← Eichor
Condition: Who Grade 4 Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Who Grade 4 Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment
Phase 1 · 1 location(s) · Plus Therapeutics · NCT05460507Atezolizumab and Pre-Surgical Brain Radiation Therapy for Glioblastoma Multiforme
EARLY_Phase 1 · 1 location(s) · Stony Brook University · NCT05423210Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
Phase 1 · 4 location(s) · Tcelltech Inc. · NCT06482905Study of Olutasidenib and Temozolomide in HGG
Phase 2 · 20 location(s) · Rigel Pharmaceuticals · NCT06161974Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Phase 2 · 3 location(s) · Academic and Community Cancer Research United · NCT06160206Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Phase 1 · 11 location(s) · Memorial Sloan Kettering Cancer Center · NCT06934889Targeted Pediatric High-Grade Glioma Therapy
Phase N/A · 21 location(s) · Nationwide Children's Hospital · NCT05839379T2 Star Magnetic Resonance Imaging and Biomarker Blood Testing to Predict the Change and Progress of Malignant Gliomas
NA · 1 location(s) · John M. Buatti · NCT07447531Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescen
Phase 3 · 2 location(s) · Lee's Pharmaceutical Limited · NCT06160492BC008-1A Injection for Recurrent CNS WHO G4 Glioma
Phase 1 · 1 location(s) · Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · NCT06773481Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
Phase 1 · 1 location(s) · Beijing Tiantan Hospital · NCT06253234A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma
NA · 3 location(s) · Mayo Clinic · NCT07091864An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Gliom
Phase 2 · 1 location(s) · Mayo Clinic · NCT06444412Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
EARLY_Phase 1 · 2 location(s) · Beijing Tiantan Hospital · NCT07648823Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastom
Phase 3 · 4 location(s) · Telix Pharmaceuticals (Innovations) Pty Limited · NCT07100730First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Phase 1 · 1 location(s) · Masonic Cancer Center, University of Minnesota · NCT07560865Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
EARLY_Phase 1 · 18 location(s) · Nationwide Children's Hospital · NCT06333899
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.